SCHEMBL5175652

SCHEMBL5175652

CC(Cc1ccc2nc(-c3c(Cl)cccc3Cl)ccc2c1)(NC(=O)[C@@H]1CCCN1S(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 3/20 0.42
GAA P10253 1/20 0.42
FKBP1A P62942 3/20 0.42
MAPT P10636 3/20 0.41
POLB P06746 2/20 0.41
TP53 P04637 2/20 0.41
ALOX15 P16050 2/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.41
PKM P14618 1/20 0.41
ITGB1 P05556 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ITGAV P06756 1/20 0.41
CCR4 P51679 3/20 0.41
HCRTR1 O43613 2/20 0.40
HCRTR2 O43614 2/20 0.40
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316739 0.89 ITGB1 (0.42) LMNAFKBP1AMAPTPOLBPKM
SCHEMBL3318583 0.82 ITGB1 (0.59) L3MBTL1LMNAMAPTITGB1SMN1; SMN2
SCHEMBL3313318 0.81 ITGB1 (0.51) L3MBTL1LMNAMAPTPOLBITGB1
SCHEMBL4627490 0.79 ITGA4 (0.49) LMNAMAPTITGB1SMN1; SMN2HCRTR1
SCHEMBL3319930 0.77 ITGB1 (0.61) LMNAMAPTPOLBALOX15MAPK1
SCHEMBL3320849 0.77 ITGB1 (0.56) L3MBTL1LMNAFKBP1ATP53ALOX15
SCHEMBL1028112 0.75 ITGB1 (0.55) LMNAMAPTPOLBALOX15MAPK1
SCHEMBL1030228 0.75 ITGB1 (0.49) LMNAMAPTPOLBALOX15MAPK1
SCHEMBL3314608 0.75 ITGB1 (0.46) GAAMAPTITGB1ITGAVITGA4
SCHEMBL5173393 0.75 ITGB1 (0.44) L3MBTL1LMNAGAAMAPTITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed